Global Liquid Biopsy Market Size and Forecast 2025–2033
How Non-Invasive Diagnostics Are Reshaping Cancer Detection and Precision Medicine Worldwide
Introduction: Liquid Biopsy Moves Into the Global Mainstream
The global liquid biopsy market is entering a phase of unprecedented growth, transforming how the world approaches cancer diagnostics and precision medicine. According to Renub Research, the market is set to soar from US$ 4.29 billion in 2024 to nearly US$ 15.46 billion by 2033, registering a robust CAGR of 15.30% from 2025 to 2033.
This surge is spurred by several converging trends: the rising global cancer burden, breakthroughs in biomarker discovery, wider availability of next-generation sequencing (NGS), and a fast-shifting preference toward non-invasive, patient-friendly diagnostic techniques. Liquid biopsy is no longer merely an alternative to traditional surgical biopsy—it's rapidly becoming a frontline tool for early detection, treatment monitoring, and personalized therapy selection.
Global Liquid Biopsy Market Overview
Liquid biopsy refers to the analysis of biological fluids—primarily blood—to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other biomarkers. Unlike tissue biopsy, liquid biopsy avoids surgical intervention, enabling clinicians to capture real-time insights into tumor evolution and treatment resistance.
Its applications have expanded far beyond oncology. Today, researchers are exploring liquid biopsy for prenatal testing, organ transplant monitoring, and early detection of chronic and genetic diseases. The speed, safety, and repeatability of the technique make it a cornerstone of emerging precision medicine ecosystems across the Americas, Europe, Asia-Pacific, and the Middle East.
Key Market Drivers in the Global Liquid Biopsy Market
1. Rising Incidence of Cancer and Chronic Diseases
Cancer remains one of the world’s most significant health challenges. In the United States alone, 2,001,140 new cancer cases and 611,720 deaths are expected in 2024, underscoring the urgent need for early and accurate detection.
Liquid biopsy offers clinicians a minimally invasive, efficient, and dynamic tool for diagnosing cancers such as:
Lung cancer
Breast cancer
Colorectal cancer
Prostate cancer
Beyond oncology, liquid biopsy technologies are increasingly being explored for cardiovascular diseases, prenatal diagnostics, and inherited genetic conditions. As global awareness of preventive healthcare grows, demand for repeatable, quick-turnaround tests continues to rise—benefiting the entire liquid biopsy ecosystem.
2. Technological Advancements in Biomarker Discovery
Breakthroughs in molecular diagnostics have accelerated liquid biopsy adoption. Advanced NGS platforms, high-precision ctDNA analysis, and sophisticated exosome profiling techniques now offer unprecedented accuracy and sensitivity.
Recent technological examples include:
August 2024: Hitachi High-Tech partnered with Gencurix to integrate digital technologies with advanced biomarker-based molecular testing.
Precision improvements in ctDNA assays are enabling earlier disease detection, real-time monitoring of therapy response, and identification of actionable genetic mutations.
These innovations continue to lower costs, expand clinical utility, and support broader commercialization of liquid biopsy tools.
3. Global Shift Toward Non-Invasive Diagnostics
The global healthcare industry is rapidly transitioning toward patient-centric, non-invasive diagnostic pathways. Liquid biopsies align perfectly with this shift:
Minimal risk and discomfort
No need for anesthesia or hospitalization
Fast processing times
Easy repeatability for continuous monitoring
This is especially beneficial for patients with late-stage cancers, for whom surgical biopsy may be impossible or risky. Moreover, home-based sample collection and decentralized diagnostic models are accelerating liquid biopsy adoption worldwide.
Regional Highlights in the Global Liquid Biopsy Market
United States Liquid Biopsy Market: World Leader in Innovation
The United States dominates the global liquid biopsy landscape, driven by:
high cancer prevalence
strong biotechnology and diagnostics infrastructure
FDA approvals of cutting-edge liquid biopsy technologies
significant investment in personalized medicine
In February 2024, Myriad Genetics acquired key testing assets from Intermountain Health, including the Precise Liquid Test—an example of how U.S. companies are consolidating strengths in oncology diagnostics.
With a strong ecosystem of biotech startups, clinical research institutions, and pharmaceutical innovators, the U.S. continues to set global benchmarks in liquid biopsy technology development and adoption.
Germany Liquid Biopsy Market: A European Powerhouse
Germany is one of Europe’s most advanced markets, fueled by:
world-class research institutions
widespread adoption of precision medicine
strong government support for medical innovation
September 2024: PreAnalytiX GmbH launched the PAXgene Urine Liquid Biopsy Set, enabling accurate cfDNA analysis from urine samples—enhancing non-invasive testing beyond blood-based assays.
With its cutting-edge biotech sector and robust regulatory framework, Germany is likely to remain a European leader in liquid biopsy innovations.
China Liquid Biopsy Market: Fastest-Growing in Asia-Pacific
China’s rapidly expanding healthcare infrastructure and rising cancer incidence make it a critical global growth center.
Key drivers include:
strong government investment in advanced diagnostics
expanding biotechnology R&D programs
fast adoption of cutting-edge liquid biopsy technologies
August 2023: China’s NMPA approved sunvozertinib for treating NSCLC with EGFR exon 20 insertion mutations—highlighting China’s commitment to precision oncology.
China represents one of the highest-growth liquid biopsy markets globally, with increasing collaborations between domestic and global biotech companies.
Brazil Liquid Biopsy Market: Leader in Latin America
Brazil dominates the Latin American liquid biopsy landscape, driven by:
rising cancer rates
improved healthcare infrastructure
strong adoption of non-invasive diagnostics
government initiatives supporting advanced medical technologies
As the region's largest economy and biotechnology hub, Brazil continues to invest heavily in modern oncology diagnostics, making it a pivotal market for global expansion strategies.
Recent Developments in the Global Liquid Biopsy Market
F. Hoffmann-La Roche Ltd.
FDA approval in 2020 for broader NSCLC companion diagnostic use
June 2022: partnered with LCRF and LCMC for early-stage lung cancer screening
Major contributor to ctDNA-based oncology solutions
Bio-Rad Laboratories
ddPCR technology enhances monitoring of cancer mutations, CTCs, and cfDNA
Widely used in academic and clinical research applications
Thermo Fisher Scientific
August 2023: launched first DNA/RNA MRD assays
Introduced digital PCR liquid-biopsy assays for the Absolute Q system
Collaborated with AstraZeneca to develop NGS-based companion diagnostics
Biocept Inc.
July 2021: secured South Korean patent for Primer-Switch technology, enabling rare biomarker detection
Guardant Health
January 2023: FDA approval for Guardant360 CDx for ESR1-mutant breast cancer
Expanded portfolio with Reveal and Response tests for early detection and recurrence monitoring
Illumina Inc.
November 2023: launched TruSight Oncology 500 ctDNA v2 assay
Expanded partnerships in NIPT, cancer genomics, and therapy selection
QIAGEN N.V.
Launched QIAseq cfDNA panels (2023)
Extended collaborations with Sysmex for ultra-sensitive liquid biopsy sequencing
Introduced EGFR Plus PCR kit for mutation detection
Exact Sciences Corporation
Expanded hereditary cancer testing via Prevention Genetics acquisition
Advancing large-scale research on liquid biopsy for genetic mutation detection
Market Segmentation
By Product
Kits & Reagents
Platforms & Instruments
Services
By Application
Cancer Therapeutics
Reproductive Health
Other Therapeutic Uses
By Circulating Biomarker
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-Free DNA (cfDNA)
By End User
Hospitals
Diagnostic Laboratories
Point-of-Care Testing
Academic Institutes
Others
By Region
Americas: United States, Canada, Mexico, Brazil
Europe: UK, Germany, France, Italy, Spain, Netherlands
Asia-Pacific: China, Japan, India, South Korea, Australia
Middle East & Africa: UAE, South Africa, Rest of the World
Company Analysis (3 Viewpoints Each)
Overview, Recent Development, Revenue
F. Hoffmann-La Roche Ltd.
Bio-Rad Laboratories
Thermo Fisher Scientific Inc.
Johnson & Johnson
Biocept Inc.
Guardant Health
Illumina Inc.
Laboratory Corporation of America Holdings
QIAGEN N.V.
Exact Sciences Corporation
Final Thoughts: The Future of Liquid Biopsy Is Real-Time, Personalized, and Global
The global liquid biopsy market is transitioning from innovation to mainstream adoption. As Renub Research forecasts, the industry’s size will more than triple by 2033—driven by advanced biomarkers, precision oncology demand, and patient preference for safer diagnostic techniques.
Liquid biopsy is not merely enhancing cancer detection; it is reshaping the entire clinical decision-making process. With increased regulatory support, accelerating R&D investments, and widespread adoption across developed and emerging economies, liquid biopsy is poised to become one of the most transformative diagnostic tools of the next decade.
About the Creator
Ben Tom
Ben Tom is a seasoned content writer with 12+ years of experience creating SEO-friendly blogs, web copy, and marketing content that boosts visibility, engages audiences, and drives results.
Day 4 of Quitting
If this is how sobriety feels, maybe it’s better to go through life a little buzzed… this, along with other hits like, I want to kill myself, I wish I was dead, and I’m going to throw myself off a bridge have been the only thoughts on rotation these past few days. I promise myself that if, in a month, I still feel like this (‘this’ meaning despondent, full of rage, and simultaneously numb) I can go back to smoking. Until mid-February though? Nicotine is off the table.
By sleepy drafts7 days ago in Longevity
The Return of the Aircraft Carrier Truman Is Being Seen as a Snub to the Navy in the War of the Future
The return of the U.S. aircraft carrier USS Harry S. Truman to active deployment has sparked debate far beyond naval circles. While some see it as a show of enduring American naval power, others interpret the move as a symbolic snub—particularly in the context of how modern warfare is rapidly evolving. In an era dominated by drones, cyber warfare, hypersonic missiles, and artificial intelligence, the decision to once again lean heavily on a traditional aircraft carrier has raised uncomfortable questions about whether the Navy is preparing for the wars of tomorrow or clinging to the strategies of yesterday. A Floating Symbol of 20th-Century Power For decades, aircraft carriers have been the ultimate symbol of U.S. military dominance. These massive floating airbases project power thousands of miles from American shores and allow the U.S. to strike almost anywhere in the world. The Truman, like other Nimitz-class carriers, represents this legacy—housing nearly 5,000 sailors, dozens of fighter jets, and unmatched logistical capability. However, critics argue that what once made carriers indispensable now makes them vulnerable. Their sheer size, cost, and visibility turn them into high-value targets in a battlefield increasingly defined by precision strikes and long-range weapons. The “War of the Future” Looks Very Different Modern conflict is no longer limited to sea, land, and air. Cyber attacks can cripple infrastructure without a single shot fired. Drones can swarm targets at a fraction of the cost of traditional aircraft. Hypersonic missiles can reach targets faster than current defenses can respond. In this context, sending a massive carrier strike group into contested waters can appear less like a strategic necessity and more like a risky gamble. Critics argue that the return of the Truman reflects an outdated mindset—one that prioritizes visible force projection over adaptability and technological evolution. A Snub to Naval Innovation? Many analysts and serving officers believe the Navy’s future lies in distributed lethality—smaller, more agile platforms networked together, harder to detect and cheaper to replace. Unmanned surface vessels, autonomous submarines, and land-based missile systems are increasingly viewed as the backbone of next-generation naval warfare. Against this backdrop, recommitting to a traditional carrier is seen by some as sidelining innovation. It sends a message that, despite years of discussion about transformation, the Navy still defaults to familiar tools when tensions rise. This perception has led to frustration among those advocating for faster modernization. They argue that resources devoted to maintaining and protecting carriers like the Truman could instead accelerate investment in emerging technologies that are more relevant to future conflicts. The Strategic Signal to Allies and Rivals Supporters of the decision counter that the Truman’s return is not about nostalgia—it’s about deterrence. Aircraft carriers remain powerful political tools. Their presence reassures allies, signals commitment, and demonstrates readiness in a way few other assets can. Yet even here, the message is mixed. To technologically advanced rivals, the deployment may signal predictability rather than strength. Adversaries have spent years developing strategies specifically designed to neutralize carriers, including anti-ship ballistic missiles and advanced surveillance systems. Cost Versus Capability The financial reality cannot be ignored. A single carrier strike group costs billions of dollars to build, maintain, and operate. In contrast, drone fleets and missile systems can be produced and deployed at a much lower cost, often with greater strategic flexibility. Critics argue that continuing to rely on carriers drains resources from areas where the Navy needs to grow most urgently. In a future conflict defined by speed, dispersion, and digital dominance, the cost-benefit equation of aircraft carriers looks increasingly questionable. Why the Carrier Still Matters—For Now Despite the criticism, aircraft carriers are not obsolete—yet. They remain unmatched in their ability to sustain prolonged air operations without relying on foreign bases. In regions where access is limited or politically sensitive, carriers still provide options no other platform can. The real issue, many experts say, is not the existence of carriers like the Truman, but over-reliance on them. Using them as one component of a broader, more flexible strategy may still make sense. Treating them as the centerpiece of future war planning may not. A Turning Point for Naval Strategy The return of the USS Harry S. Truman highlights a deeper tension within modern military thinking. It represents a crossroads between tradition and transformation, between proven power and emerging threats. Whether history views this moment as a wise assertion of strength or a missed opportunity for innovation will depend on what comes next. If the Navy pairs legacy platforms with bold technological change, the carrier’s return may be justified. If not, it risks becoming a powerful symbol—not of dominance, but of reluctance to adapt in a rapidly changing world.
By Fiazahmedbrohi a day ago in Longevity
Comments
There are no comments for this story
Be the first to respond and start the conversation.